Brought to you by 
Lilly enlists Innovex to help launch Cymbalta
20 May 2005
Executive Summary
Innovex, the contract drug commercialization unit of CRO Quintiles Transnational, will supply and pay for more than 500 sales reps to help Lilly with the US launch of its Cymbalta (duloxetine HCl), an antidepressant currently under review for FDA approval.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly enlists Innovex to help launch Cymbalta
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice